Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Forbes on BTD published in Nature.

<< Previous

Bullboard Posts

Next >>

Comment by reconsideron Nov 24, 2024 8:41pm

217 Views

Post# 36328331

RE:RE:Forbes on BTD published in Nature.

Just look at IBRX. They received BTD in December '19.
$1.5 to $7 in 1 month (x4.5).
$13 in July '20 (x8.5).
$30 in Feb '21 (x15).
Had a lot to do with COVID stonking also, but never the less.
I can't see how an unknown microcap company at $50M wouldn't have a solid value raise if their wonder particle get's BTDed. That would put us in the radar of every single analyst checking the FDA and a crucial steping stone towards joint venture or acquisition.
Fingers crossed to a Happy Thanksgiving. This week could mean news.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023